Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | CASP1 | P29466 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CES2 | O00748 | 1/20 | 0.64 |
| ▸ | GALR3 | O60755 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GSTA1 | P08263 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29404037 | 1.00 | CYP2C9 (0.64) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| SCHEMBL30352763 | 0.94 | CYP2C9 (0.72) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| SCHEMBL129669 | 0.94 | CYP2C9 (0.72) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| SCHEMBL9487167 | 0.92 | CYP2C9 (0.69) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| SCHEMBL309016 | 0.83 | HPGD (0.69) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| 1,4-Butanediol SCHEMBL11023193 | 0.83 | CYP2C9 (0.58) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| Acetic Acid SCHEMBL27571040 | 0.80 | GSTA1 (0.47) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| SCHEMBL5888486 | 0.80 | HPGD (0.64) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| Gentisic Acid SCHEMBL4923463 | 0.79 | CA1 (0.87) | CYP2C9HPGDALOX15CASP1CYP2C19 | |
| SCHEMBL29355897 | 0.79 | CES2 (1.00) | CYP2C9HPGDALOX15CASP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1072 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2841066-B1 | ANTI-INFLUENZA AGENT CONJUGATED TO ANTI-INFLAMMATORY AGENT | ACADEMIA SINICA (TW) | 2021-02-17 | — | — | EP | claimed |
| US-10758626-B2 | Polymer conjugate comprising a bioactive agent | POLYACTIVA PTY LTD (AU) | 2020-09-01 | — | — | US | claimed |
| EP-3524272-A1 | ENHANCED ANTI-INFLUENZA AGENTS CONJUGATED WITH ANTI-INFLAMMATORY ACTIVITY | Academia Sinica (TW) | 2019-08-14 | — | — | EP | claimed |
| US-20180303948-A1 | POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2018-10-25 | — | — | US | claimed |
| EP-3347052-A1 | POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT | Polyactiva Pty Ltd (AU) | 2018-07-18 | — | — | EP | claimed |
| US-9968684-B2 | Polymer-NSAID conjugate | POLYACTIVA PTY LTD (AU) | 2018-05-15 | — | — | US | claimed |
| EP-2863921-B1 | POLYMER-NSAID CONJUGATE | POLYACTIVA PTY LTD (AU) | 2018-04-18 | — | — | EP | claimed |
| WO-2017041142-A1 | POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2017-03-16 | — | — | WO | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-20150150999-A1 | POLYMER-NSAID CONJUGATE | POLYACTIVA PTY LTD (AU) | 2015-06-04 | — | — | US | claimed |
| US-20040023890-A1 | Drugs for diabetes | NICOX S.A. (FR) | 2004-02-05 | — | — | US | claimed |
| WO-2004005313-A2 | HYBRID MOLECULES OF MACROLIDES WITH STEROID/NON-STEROID ANTI-INFLAMMATORY, ANTINEOPLASTIC AND ANTIVIRAL ACTIVE MOLECULES | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (US) | 2004-01-15 | — | — | WO | claimed |
| WO-2004005309-A2 | NOVEL NONSTEROIDAL ANTI-INFLAMMATORY SUBSTANCES, COMPOSITIONS AND METHODS FOR THEIR USE | PLIVA - ISTRAZIVACKI INSTITUT D.O.O. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | MCNEIL-PPC, INC | 2003-12-25 | — | — | US | claimed |
| US-20030180357-A1 | Pharmaceutical tablet | MCNEIL-PPC, INC | 2003-09-25 | — | — | US | claimed |
| CN-1433396-A | Pharmaceutical compounds | NICOX SA (FR) | 2003-07-30 | — | — | CN | claimed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | claimed |
| CN-1358178-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-07-10 | — | — | CN | claimed |
| CN-1354740-A | Pharmaceutical compounds | NICOX SA (FR) | 2002-06-19 | — | — | CN | claimed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180357-A1 | Pharmaceutical tablet | GYPA, SORD, SRI | CYP2C9 168/4885HPGD 313/4885ALOX15 829/4885 |
| US-20150150999-A1 | POLYMER-NSAID CONJUGATE | PTGS1, PTGES3, PTGES | CYP2C9 193/4885HPGD 36/4885ALOX15 24/4885 |
| US-10758626-B2 | Polymer conjugate comprising a bioactive agent | MSN, PAM, PARG | CYP2C9 963/4885HPGD 100/4885ALOX15 24/4885 |
| US-20040023890-A1 | Drugs for diabetes | SLC5A2, ADORA2B, UGT2B7 | CYP2C9 56/4885HPGD 1309/4885ALOX15 437/4885 |
| US-20180303948-A1 | POLYMER CONJUGATE COMPRISING A BIOACTIVE AGENT | MSN, PAM, PARG | CYP2C9 963/4885HPGD 100/4885ALOX15 24/4885 |
| US-20030235617-A1 | Pharmaceutical dosage form for mucosal delivery | SI, UGGT1, GYPA | CYP2C9 104/4885HPGD 188/4885ALOX15 335/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | CYP2C9 294/4885HPGD 7/4885ALOX15 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.